



COMPANY OVERVIEW

Orogenics acquire assets related to proprietary neurological drug therapies, including a proprietary formulation and nasal delivery system. The assets include drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C.

Orogenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.

RECENT NEWS

Orogenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18 2024, 7:00 AM EDT

STOCK OVERVIEW

Symbol	OGEN
Exchange	NYSE American
Market Cap	3.65m
Last Price	\$1.42
52-Week Range	\$1.26 - \$7.74

03/19/2024 04:00 PM EDT

INVESTOR RELATIONS

LHA Investor Relations
Tirth T. Patel
Vice President
T: 212.201.6614
tpatel@lhai.com

MANAGEMENT TEAM

Janet Huffman

Chief Financial Officer

J. Michael Redmond

President & Interim Principal Executive Officer

Christine M. Farrell

Vice President of Finance

ORAGENICS, INC.

4902 Eisenhower Blvd.
Suite 125
Tampa, FL 33634
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.